Journal of Clinical Oncology
Articles in this Issue
Evaluation of the efficacy and safety of anlotinib in postoperative non-pCR non-small cell lung cancer.
e20005 Background: Several phase III studies have confirmed the efficacy and safety of neoadjuvant immunochemotherapy for resectable non-small cell lung c...
Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.
10507 Background: Obesity is a major risk factor for cancer development. However, whether glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of...
Daily low-dose oral temozolomide as maintenance therapy following doxorubicin plus dacarbazine in advanced leiomyosarcoma patients: An observational study.
11559 Background: Doxorubicin (Dox) combined with dacarbazine (DTIC) is a standard first-line regimen for advanced leiomyosarcoma (LMS), but its long-term...
Overall survival outcomes in stage III melanoma patients treated with adjuvant immunotherapy vs targeted therapy: A National Cancer Database analysis.
9575 Background: Adjuvant therapy with immunotherapy (IO) and targeted therapy (TT) has significantly improved outcomes in Stage III melanoma following su...
Advancing equity and collaboration in a dedicated young onset cancer clinic: A prospective study.
1546 Background: Coordinated young onset cancer (YOC) clinics improve patient experience and access to supportive services. However, geographic and ethnic...
The TIGOS trial: A randomized, double-blind phase 3 trial of atigotatug + nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with 1L extensive-stage small cell lung cancer (ES-SCLC).
TPS8127 Background: Atigotatug is an innate immune inducer monoclonal antibody that binds fucosyl-monosialoganglioside-1 (fuc-GM1) with high affinity and...
Early-onset gastric cancer: A comparison of metastatic and locoregional disease.
e16036 Background: The incidence of metastatic gastric cancer among young adults is rising and has a dismal prognosis with 5-year survival of only 4%. Lit...
The efficacy and safety of radiotherapy combined with tyrosine kinase inhibitors in the treatment of advanced GIST.
e23519 Background: Phase II multicenter study (identifier NCT00515931) have found that gastrointestinal stromal tumor (GIST) is moderately sensitive to ra...
Triple negative breast cancer: Insights from the Mexican population.
e13148 Background: Breast cancer (BC) is the leading cause of cancer related deaths among women worldwide, driven by multifactorial influences resulting i...
Mortality in survivors of childhood cancer diagnosed with subsequent thyroid cancer: A report from the Childhood Cancer Survivor Study.
10020 Background: Childhood cancer survivors are at increased risk of developing a subsequent thyroid cancer, particularly following radiotherapy. In the...
Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma.
6026 Background: Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is characterized by hyperactivation of the cyclin-depen...
Comprehensive molecular and immunohistochemical profiling of endometrial carcinomas: Insights into subtype-specific characteristics.
e17641 Background: Endometrial carcinomas exhibit significant molecular and histopathological heterogeneity. This study analyzes 171 samples to uncover su...
Chemotherapy regimen and cisplatin dose effects on survival in neoadjuvant treatment of urothelial muscle-invasive bladder cancer.
e16579 Background: Neoadjuvant chemotherapy (NACT) in patients (pts) with muscle-invasive bladder cancer (MIBC) significantly improves treatment outcomes....
Liposomal vs conventional doxorubicin as first-line therapy in advanced soft tissue sarcomas: A tertiary US center’s 8.5-year experience.
e23533 Background: Patients with advanced soft tissue sarcoma (STS) are commonly treated with either conventional doxorubicin (dox) or liposomal doxorubic...
The classification of uncertain histologies based on cfDNA fragmentomic analysis in patients with uncommon cancers screened for NCI-MATCH.
2557 Background: The NCI Molecular Analysis for Therapy Choice (NCI-MATCH) was a precision medicine trial that assigned targeted treatments to patients in...
First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results.
e13138 Background: TROP2 and HER3 are both highly expressed in TNBC and associated with worse survival. JSKN016 is a bispe...
Major adverse cardiovascular complications event outcomes in liver cancer.
e16336 Background: Liver cancer is a significant global health burden with racial and ethnic disparities affecting disease outcomes, healthcare resource u...
Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.
4583 Background: For cis-ineligible pts with MIBC undergoing radical cystectomy and pelvic lymph node dissection (RC+PLND), no neoadjuvant treatment optio...
Fibroblast-activating protein (FAP) expression and first clinical utility of <sup>68</sup> Ga-FAPI-PET-CT in testicular cancer patients.
e17019 Background: The fibroblast activation protein (FAP) is usually expressed on the surface of fibroblasts within the tumor and overexpression is assoc...
A phase I/II trial of high-dose methotrexate (HDMTX) followed by prophylactic glucarpidase in patients with impaired renal function and central nervous system lymphoma (CNSL).
7081 Background: HDMTX is a key component of treatment protocols for CNSL patients (pts), but impaired renal function in elderly or comorbid pts limits it...
Oncologists’ happiness at work and integrative oncology.
e23127 Background: Oncology care teams often face long hours and high patient volumes in a profession that is emotionally and mentally demanding. Whole pe...
Anti-TROP2 ADC ESG401 in a master protocol clinical trial for salivary gland cancer based on molecular typing.
6100 Background: Salivary gland carcinomas (SGC) are rare, with limited prospective clinical outcome data. There is no sta...
Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.
6059 Background: A randomized phase II/III trial (JCOG1008) suggested that postoperative chemoradiotherapy (POCRT) with weekly cisplatin is a treatment op...
Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).
5059 Background: Patients with NEPC are often treated with platinum-based chemotherapy but novel therapies with favorable efficacy and safety profiles are...
Effect of enrollment in a clinical trial on treatment outcomes of patients with pancreas cancer.
e16445 Background: Clinical trials serve as a critical pathway to novel, potentially life-saving treatments and provide structured care, rigorous monitori...